U.S., June 2 -- ClinicalTrials.gov registry received information related to the study (NCT07617077) titled 'NASVAL-SVT: Nasal Swab Versus Modified Valsalva for Supraventricular Tachycardia' on May 23.
Brief Summary: Supraventricular tachycardia (SVT) is a common heart rhythm disorder seen in emergency departments, causing a rapid heartbeat (typically 150-250 beats per minute). The current best non-drug treatment, the modified Valsalva maneuver (mVM), successfully restores normal rhythm in about 43% of cases. When these maneuvers fail, intravenous adenosine is used, which, while effective, can cause brief but distressing side effects such as chest tightness, shortness of breath, and intense anxiety.
During the COVID-19 pandemic, some patie...